e17000 Background: Squamous cell carcinoma of the head and neck (SCCHN) is a
disfiguring and potentially fatal condition. Cetuximab is a new therapeutic option which has …

5563 Background: Conventional dosing of C (400 mg/m2 loading dose, 250 mg/m2 weekly)
yields response rate of approximately 13% among pts with R/M HNSCC. Conventional …

We discuss the results of the phase III EXTREME (Erbitux in First-Line Treatment of
Recurrent or Metastatic Head and Neck Cancer) trial. In this study, 442 untreated patients …

Introduction: The standard of care for patients with locally-advanced head and neck cancer
is chemoradiation or surgical resection followed by radiation treatment with or without …

Objective. To review the current state of the data on the use of cetuximab in head and neck
squamous cell carcinoma (HNSCC). Data Sources. The National Center for Biotechnology …

Purpose This was an open, randomized, multicenter, phase I/II study to investigate the safety
and tolerability of cetuximab in the first-line treatment of recurrent/metastatic squamous cell …

Background and Objective: Cetuximab combined with radiotherapy or chemotherapy has
been used to treat head and neck cancer in recent years, but few reports are available in …

Encouraging data for targeted therapy in head-and-neck squamous cell carcinoma are
opening new options for treatment. Phase III trials of cetuximab, an antibody directed against …

Context: Treatment outcome for locally advanced squamous cell carcinoma of the head and
neck is poor. Recently, anti-epidermal growth factor monoclonal antibodies, such as …

The Head and Neck Squamous Cell Cancer (HNSCC) is the most common type of head and
neck cancer (more than 90%), and all over the world more than a half million people have …